1. Home
  2. BDSX vs NYXH Comparison

BDSX vs NYXH Comparison

Compare BDSX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$14.59

Market Cap

143.2M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$2.71

Market Cap

134.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
NYXH
Founded
2005
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Precision Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.2M
134.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BDSX
NYXH
Price
$14.59
$2.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$32.50
$9.33
AVG Volume (30 Days)
64.7K
32.9K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,499,000.00
N/A
Revenue This Year
$25.26
$213.98
Revenue Next Year
$19.15
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.26
$2.72
52 Week High
$20.21
$8.59

Technical Indicators

Market Signals
Indicator
BDSX
NYXH
Relative Strength Index (RSI) 55.64 37.12
Support Level $13.46 N/A
Resistance Level $16.38 $3.36
Average True Range (ATR) 1.00 0.16
MACD 0.08 -0.02
Stochastic Oscillator 42.83 0.00

Price Performance

Historical Comparison
BDSX
NYXH

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: